artemether

alpha-Artemether is a Quinghaosu derivative with antifungal and antimalarial activity.

Artemether (CGP 56696) is an antimalarial agent used to treat acute uncomplicated malaria.

Artemether-d3 is the deuterated form of Artemether, an antimalarial compound effective against resistant strains of Plasmodium falciparum (malaria).

Artemether (Standard) is the standard substance of Artemether, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Artemether (CGP 56696) is an antimalarial agent used to treat acute uncomplicated malaria.

Lumefantrine (dl-Benflumelol) is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

ART838 is a dimeric pimeloyl urea compound notable for its potent anti-leukemic activity and favorable pharmacological properties. In vitro, ART-838 exhibits submicromolar inhibitory concentrations against all leukemia cell lines, demonstrating anti-leukemic efficacy 88 times greater than artemether. This compound remains in the body for extended periods and works synergistically with other anti-leukemic agents and novel kinase inhibitors to suppress leukemia cell growth. In immunodeficient NOD-SCID-IL2Rgnull (NSG) mice, ART-838 attains a plasma half-life longer than that of artemether, sustaining effective anti-leukemic concentrations for over 8 hours. Intermittent ART-838 treatment notably inhibited the growth of acute leukemia xenografts and primary grafts in NSG mice, surpassing the efficacy of artemether.

Lumefantrine-d9 is a deuterated compound of Lumefantrine. Lumefantrine has a CAS number of 82186-77-4. Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

Dihydroartemisinin diketo aldehyde is an impurity of Artemether.